The Upcoming Shroom Boom
Could Catapult This Psychedelics
Company Out of the Galaxy
 Greetings Fellow Investor, As fast as the cannabis market exploded from zero to $US24 billion, the psychedelic drug market could go even higher, and more importantly… even faster! That's because researched psychedelic drugs like psilocybin (aka magic mushrooms), MDMA and ketamine could completely revolutionize mental healthcare as we know it. It's the biggest mental health breakthrough in 50 years, and will change the lives of countless millions of patients suffering from anxiety, depression, PTSD and other mental health disorders. The total worldwide addressable mental health sector is pegged at US$70 billion. After decades of research, a growing body of evidence shows that psychedelics have a better ability to improve mental health symptoms than any current treatment. Major studies from Yale, Johns Hopkins, and the US National Institute of Mental Health are giving psychedelic drugs legitimacy, helping to open a path to a brand new multi-billion dollar market. The World's Smartest Business People Are Betting
on the Enormous Rise in the Psychedelics Space Investors like PayPal founder Peter Thiel; GoDaddy founder Bob Parsons; and venture capitalists George Sarlo, Steve Cohen, and Mike Novogratz are all in. They're putting big money behind companies like Compass Pathways and Mind Medicine that are still in the early stages of drug development, years away from seeing revenue. There are several big heavyweights that are backing this little-known company taking a completely different path to early profits, while at the same time establishing a meaningful scientific foothold in the space. The Billion-Dollar Backers Behind This
Company You Are About to Discover Paul Rosen, co-founder of PharmaCan Capital Corp. and its first President and CEO, is betting that the company's strategy to acquire immediate revenue-generating assets will pay off in a big way. So are other top venture capitalists and market leaders, including Kraig Fox, former managing director at investment firm Guggenheim Partners; philanthropist Garyn Angel; serial entrepreneur and venture capitalist Martin Tobias; and Apollo Neuroscience founder Dave Rabin, MD, PhD. Immediate Path to Profits This company's strategy is to focus initially on immediate positive revenue derived from legal psychedelics. They will do this by growing a chain of retail level medical clinics offering mental health and wellness treatments with the only psychedelic drug that is fully FDA-approved and has a decades-long history of safe use. Much of the emerging research on the superiority of psychedelic drugs for mental health conditions has been conducted using this one specific drug. Medical scientists from Yale say "this is a game changer," and a "miracle drug." The director of the US National Institute of Mental Health says it makes "a life-changing impact." This company also recently acquired a fully licensed top science lab in Canada with existing blue chip clients already bringing revenue and positive cash flow, and further allowing the development of important Intellectual Property (IP) of psilocybin-related research and ownership surrounding mental health. To Discover This Trailblazing Psychedelics Stock
& My Top 7 Reasons to Consider This Company… Click Here
I'm in, how about you?
Blake Desaulniers, Contributor
For Investor News Service
P.S. This opportunity is as fresh as it gets. It's like early 2016 in the cannabis revolution, and you remember how that went: savvy cannabis investors who bought Canopy Growth early realized gains of up to 3,220 %. Now it's a new revolution. And it could be even bigger. Make sure you don't miss out. P.P.S. Next to leading Compass Pathways, this company is one of the very rare psychedelics companies with support from big name billion-dollar value creators who are either on the board of directors or serve in an advisory capacity. _________________________ DISCLOSURE: The company discussed in this email is a Blake Desaulniers portfolio holding. Blake Desaulniers has not received any payment for the writing of this email or linked article / report. SPONSORED ARTICLE: Investing in any securities is highly speculative. Please be sure to always do your own due diligence before making any investment decisions. Read our full disclaimer here 
| 
No comments:
Post a Comment